JP2024546096A5 - - Google Patents

Info

Publication number
JP2024546096A5
JP2024546096A5 JP2024533985A JP2024533985A JP2024546096A5 JP 2024546096 A5 JP2024546096 A5 JP 2024546096A5 JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024546096 A5 JP2024546096 A5 JP 2024546096A5
Authority
JP
Japan
Prior art keywords
seq
antigen
deletion
substitution
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/052099 external-priority patent/WO2023107538A2/en
Publication of JP2024546096A publication Critical patent/JP2024546096A/ja
Publication of JP2024546096A5 publication Critical patent/JP2024546096A5/ja
Pending legal-status Critical Current

Links

JP2024533985A 2021-12-07 2022-12-07 コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 Pending JP2024546096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163286719P 2021-12-07 2021-12-07
US63/286,719 2021-12-07
PCT/US2022/052099 WO2023107538A2 (en) 2021-12-07 2022-12-07 Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides

Publications (2)

Publication Number Publication Date
JP2024546096A JP2024546096A (ja) 2024-12-17
JP2024546096A5 true JP2024546096A5 (cg-RX-API-DMAC7.html) 2025-12-09

Family

ID=86731156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533985A Pending JP2024546096A (ja) 2021-12-07 2022-12-07 コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤

Country Status (4)

Country Link
US (1) US20250313648A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546096A (cg-RX-API-DMAC7.html)
WO (1) WO2023107538A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503203A (ja) * 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのcspg4に対するモノクローナル抗体
US10093745B2 (en) * 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
EP3218413A4 (en) * 2014-11-12 2018-03-28 Memorial Sloan-Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
WO2016164429A1 (en) * 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 chimeric antigen receptors
AU2019287676A1 (en) * 2018-06-13 2021-01-07 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells

Similar Documents

Publication Publication Date Title
AU2014352475B2 (en) Anti-HER2 antibody and conjugate thereof
JP2022064924A5 (cg-RX-API-DMAC7.html)
JP7579990B2 (ja) 抗ネクチン-4抗体およびその使用
JP2018520092A5 (cg-RX-API-DMAC7.html)
JP2019528251A (ja) グリコシル化pd−l1に結合する抗体の組合せを使用するがんの処置および治療の方法
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2018524296A (ja) Cd123抗体及びその複合体
TW202146456A (zh) 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
JP2022527151A5 (cg-RX-API-DMAC7.html)
JP2020530285A5 (cg-RX-API-DMAC7.html)
JP7531224B2 (ja) ポドカリキシン及びtra関連抗体、調製方法、並びに抗癌治療剤としての使用
JP2014515600A5 (cg-RX-API-DMAC7.html)
CN112175082B (zh) 抗叶酸受体α抗体、其缀合物及其用途
CN114127117A (zh) 用于偶联的多肽复合物及其应用
JP2022500455A5 (cg-RX-API-DMAC7.html)
JP2025512953A5 (cg-RX-API-DMAC7.html)
CN119421894A (zh) 具有ph依赖性结合的ptk7结合蛋白及其用途
TWI822815B (zh) 抗-人類pd-l1之抗體及其用途
Zhang et al. A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer
JP2026513240A (ja) Trop2結合タンパク質およびその使用
WO2019087994A1 (ja) 固形腫瘍の治療に有益な抗体およびその抗体-薬物コンジュゲート並びにこれらを含む抗がん剤
WO2023169328A1 (zh) 一种靶向ror1的结合分子及其应用
TW202309099A (zh) 結合於heg1蛋白質之人源化抗體
JP2023536630A5 (cg-RX-API-DMAC7.html)
WO2026098695A1 (zh) 一种标记抗体的方法